Description

Alaktin (Cabergoline) tablets 0.5 mg. N8 vial

Ingredients

Active ingredient: Cabergoline 0.5 mg per tablet.

Dosage

Dosage: The usual recommended dose is 0.25 mg twice a week. Dosage may vary based on individual response and medical condition.

Indications

Indications: Alaktin (Cabergoline) is indicated for the treatment of hyperprolactinemia, disorders associated with high levels of prolactin hormone.

Contraindications

Contraindications: Do not use Alaktin (Cabergoline) if you are allergic to cabergoline or any other ingredients in the product. Consult a healthcare provider before use.

Directions

Directions: Take Alaktin (Cabergoline) tablets orally with or without food as directed by your doctor. Follow the dosage instructions carefully.

Scientific Evidence

Cabergoline, the active ingredient in Alaktin, is a dopamine receptor agonist that works by reducing the secretion of prolactin from the pituitary gland. Studies have shown that cabergoline is effective in normalizing prolactin levels in patients with hyperprolactinemia. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated the efficacy of cabergoline in improving symptoms associated with hyperprolactinemia.

Additional Information

It is important to adhere to the prescribed dosage and follow-up appointments with your healthcare provider while using Alaktin (Cabergoline) to monitor treatment response and any potential side effects. Inform your doctor about any other medications or supplements you are taking before starting Alaktin.

Pharmacological Effects: Cabergoline acts on dopamine receptors in the brain, inhibiting the secretion of prolactin. This helps in reducing prolactin levels in conditions like hyperprolactinemia.

Clinical Trials: Clinical trials have shown that cabergoline is effective in treating hyperprolactinemia with a favorable safety profile. A study published in the European Journal of Endocrinology demonstrated the long-term efficacy and tolerability of cabergoline in patients with hyperprolactinemia.